caa a22 4500 60549147X CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0818-3 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0818-3 Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer [Elektronische Daten] [Atsuki Arimoto, Keisuke Uehara, Toyonori Tsuzuki, Toshisada Aiba, Tomoki Ebata, Masato Nagino] Background: The role of bevacizumab (Bev) in neoadjuvant chemotherapy (NAC) without radiotherapy for rectal cancer has not been fully discussed. The purpose of this study is to assess the clinicopathological benefit of Bev in NAC for rectal cancer and to investigate its influence on microvessel status in cancerous tissue. Methods: Data on 47 patients with rectal cancer, who received NAC with or without Bev between August 2008 and November 2012, were analyzed retrospectively. The objective response was evaluated using the maximum tumor diameter. Tumor regression grade 3/4 was classified as a pathological response. Results: Thirty-one patients (66%) received NAC that included Bev and the other 16 patients were treated without Bev. The objective response rate was significantly higher in the Bev group than in the non-Bev group (64.5 vs. 25.0%, p=0.015). The rate of pathological response was much higher in the Bev group (41.9%) than in the non-Bev group (12.5%), but did not reach significant difference (p=0.052). Microvessel density (MVD) in the resected cancerous tissue was significantly lower in the Bev group than in the non-Bev group. Conclusions: We have confirmed that objective and pathological responses were better in patients treated with NAC that included Bev than in those who received NAC without Bev. Additionally, MVD in tumor tissues was inhibited in the patients treated with Bev. To investigate the impact of Bev in NAC on long-term survival, further follow-up is required. Japan Society of Clinical Oncology, 2015 Bevacizumab nationallicence Neoadjuvant chemotherapy nationallicence Microvessel density nationallicence Rectal cancer nationallicence Arimoto Atsuki Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut Uehara Keisuke Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut Tsuzuki Toyonori Department of Pathology, Nagoya Daini Red Cross Hospital, 2-9 Myoken-cho, Showa-ku, 466-8650, Nagoya, Japan aut Aiba Toshisada Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut Ebata Tomoki Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut Nagino Masato Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 935-942 1341-9625 20:5<935 2015 20 10147 https://doi.org/10.1007/s10147-015-0818-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0818-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Arimoto Atsuki Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut NATIONALLICENCE 700 1- Uehara Keisuke Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut NATIONALLICENCE 700 1- Tsuzuki Toyonori Department of Pathology, Nagoya Daini Red Cross Hospital, 2-9 Myoken-cho, Showa-ku, 466-8650, Nagoya, Japan aut NATIONALLICENCE 700 1- Aiba Toshisada Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut NATIONALLICENCE 700 1- Ebata Tomoki Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut NATIONALLICENCE 700 1- Nagino Masato Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 935-942 1341-9625 20:5<935 2015 20 10147